Ocugen, Inc. (OCGN): Operating Cash Flow
-$56.96M
Year ended 2025-12-31
-$60.87M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$56.96M | n/m | 2026-03-04, From 2025-01-01 |
| 2024-12-31 | -$42.14M | n/m | 2026-03-04, From 2024-01-01 |
| 2023-12-31 | -$62.05M | n/m | 2025-03-05, From 2023-01-01 |
| 2022-12-31 | -$60.08M | n/m | 2024-04-16, From 2022-01-01 |
| 2021-12-31 | -$47.94M | n/m | 2023-02-28, From 2021-01-01 |
| 2020-12-31 | -$14.71M | n/m | 2022-02-28, From 2020-01-01 |
| 2019-12-31 | -$16.89M | n/m | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | -$11.63M | n/c | 2020-03-27, From 2018-01-01 |
| 2017-12-31 | -$23.02M | n/m | 2019-03-22, From 2017-01-01 |
| 2016-12-31 | -$25.74M | n/m | 2018-03-15, From 2016-01-01 |
| 2015-12-31 | -$30.03M | n/m | 2017-03-16, From 2015-01-01 |
| 2014-12-31 | -$17.94M | n/a | 2016-03-10, From 2014-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Ocugen, Inc. (OCGN) | 2025-12-31 | -$56.96M | n/m |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | -$162.56M | n/m |
| CG Oncology, Inc. (CGON) | 2025-12-31 | -$132.35M | n/m |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | -$718.0K | n/m |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | -$345.01M | n/m |
| Surrozen, Inc. (SRZN) | 2025-12-31 | -$30.24M | n/m |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | -$121.18M | n/m |
| Dyadic International Inc (DYAI) | 2025-12-31 | -$5.70M | n/m |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | -$106.08M | n/m |
Compare OCGN, PRME, CGON, ZEOX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗